Gentaur offers a broad selection of research-grade biosimilar antibodies engineered for cost-effective, reproducible, and functionally equivalent performance compared to original biologics. Our biosimilars are validated in applications such as ELISA, flow cytometry (FCM), functional assays, and in vivo studies, making them ideal tools for preclinical immunotherapy research, pathway elucidation, and dr ug mechanism analysis.
t
What Are Biosimilar Antibodies ?
Biosimilar antibodies are biologics that closely mimic the structure, binding behavior, and biological activity of reference therapeutic antibodies (e.g., Adalimumab, Nivolumab, Trastuzumab), but are not identical clones. While generic drugs are chemically indistinguishable from originators, biosimilars are functionally comparable—demonstrating equivalent efficacy, affinity, and target specificity for use in research-grade applications.
s
Validated Biosimilars with Functional Equivalence
Gentaur’s biosimilar antibody catalog includes validated references for key targets in oncology, autoimmune disease, infectious disease, and inflammation research. Our products are characterized by :
✅ High binding affinity (ELISA-based EC₅₀ values).
✅ Functional equivalence to original biologics.
✅ Batch-to-batch reproducibility.
✅ Optimized for non-clinical use.
✅ Competitive pricing & EU-wide fast delivery.
Comparative Binding Activity Examples
Biosimilar Antibody | Target | EC₅₀ (Binding Affinity) |
---|---|---|
Adalimumab | TNFα | 142.1 ng/mL |
Nivolumab | PD-1 | 97.73 ng/mL |
Bevacizumab | VEGF165 | 97.73 ng/mL |
Necitumumab | EGFR | 159.1 ng/mL |
Biosimilar Antibodies Product List (Selection)
Product Code | Gentaur Biosimilar | Target |
---|---|---|
GMA-TNFRSF9 | Urelumab | CD137 / TNFRSF9 |
GMA-CD19 | Blinatumomab | CD19 / CD3E (Bispecific) |
GMA-ERBB2 | Trastuzumab | HER2 (ERBB2) |
GMA-IL-4RA | Dupilumab | IL-4 Receptor Alpha |
GMA-PD-1 | Nivolumab / Pembrolizumab | PD-1 |
GMA-APP | Donanemab | APP |
GMA-PCSK9 | Bococizumab | PCSK9 |
GMA-MS4A1 | Rituximab / Teclistamab | CD20 |
GMA-PVRL4 | Enfortumab | Nectin-4 |
GMA-CD74 | Milatuzumab | CD74 |
